Morning, Thursday, 25th April 2019
THIS EVENT IS CPD CERTIFIED
Please note the date of this seminar has changed.
This conference will discuss key issues in pharmaceutical pricing, access to medicines and priorities for the Voluntary Scheme for Branded Medicines Pricing and Access, which succeeds the Pharmaceutical Price Regulation Scheme.
Delegates will consider the impact of the new 5-year scheme on potential savings to the NHS, patient access and medicines innovation - with government announcing expected savings of around £930m in 2019.
Planned sessions will assess how industry will be affected by the Voluntary Scheme - following the introduction of a 2% cap on the growth in sales of branded medicines - as well as challenges for NICE as they aim to quicken their assessments of new medicines.
With the Government announcing a review into overprescribing in the NHS, the agenda also looks at what further options could be available for supporting medicine optimisation and ensuring patients are receiving the most up to date treatment.
The seminar also follows the publication of the Government’s 5-year action plan for controlling antimicrobial resistance, which includes a commitment from NHS England and NICE to explore a new payment model for pharmaceutical companies based on the value of the medicines, rather than the quantity sold.
Attendees will also discuss next steps for reducing expenditure on medicines and the role of NHS England in accelerating innovation, following the publication of the NHS Long Term Plan, which includes goals to deliver better value from the NHS’ expenditure on medicines, whilst encouraging the adoption of proven innovations.
Further discussion is planned on the challenges of bringing new products to the market - including the impact of the Accelerated Access Collaborative, designed to support the breakthrough of new medicine and technology, as well as issues surrounding intellectual property - with the House of Lords debating the Patents (Amendment) (EU Exit) Regulations 2018 - including how changes to the duration of patents may affect incentives for companies to develop new medicines.